BOBULSKY SUSAN sold $95K of ADPT
BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 5,000 shares of Adaptive Biotechnologies Corp (ADPT) at $19.00 on 2026-06-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size, price, and post-transaction holdings, but it is pre-arranged under Rule 10b5-1, reducing interpretive weight.
Market read
Traders may note the disclosed insider sale, but the 10b5-1 framing suggests limited incremental information for valuation.
What to watch
The article provides only the sale details; it does not indicate whether other insiders or large holders changed positions around the same time.
Background
The article is an SEC EDGAR Form 4 insider transaction disclosure for Adaptive Biotechnologies.
Ticker impact
SEC Form 4 shows Adaptive Biotechnologies CCO Susan Bobulsky sold 5,000 shares at $19 on 2026-06-11 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The disclosure is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan and no accompanying fundamental catalyst.
Market effects
No sector-level implications; this is company-specific insider liquidity activity.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can still be interpreted as reduced confidence by some traders.
Key entities
- issuerAdaptive Biotechnologies Corp
Subject of the Form 4 insider transaction disclosure.
- insiderSusan Bobulsky
Chief Commercial Officer (MRD) who sold shares.